Koshinski Asset Management
AUPH icon

Koshinski Asset Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Koshinski Asset Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100
Closed -$1.24K – 675
2022
Q1 		$1.24K Hold
100
– – ﹤0.01% 2039
2021
Q4 		$2.29K Hold
100
– – ﹤0.01% 1962
2021
Q3 		$2.21K Buy
+100
New +$1.59K ﹤0.01% 2000

Other funds holding AUPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Koshinski Asset Management's AUPH Position: Q2 2022 in Review

Koshinski Asset Management sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2022, closing a stake of 100 shares — an estimated $1.24K sold.

Koshinski Asset Management first reported a position in AUPH in Q3 2021 and held it in 3 quarters. The position peaked at $2.29K in Q4 2021. 199 funds tracked by Wall St. Rank hold AUPH as of Q2 2022.

  • Koshinski Asset Management reported no remaining Aurinia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Koshinski Asset Management sold 100 Aurinia Pharmaceuticals shares in Q2 2022, an estimated $1.24K.
  • Koshinski Asset Management first reported a position in Aurinia Pharmaceuticals in Q3 2021 and held it in 3 quarters.
  • Koshinski Asset Management's Aurinia Pharmaceuticals position peaked at $2.29K in Q4 2021.
  • 199 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2022.

Based on Koshinski Asset Management's 13F filing for Q2 2022, filed 12 Jul 2022.